↓ Skip to main content

Dove Medical Press

Treatment and outcomes of non-small-cell lung cancer patients with high comorbidity

Overview of attention for article published in Cancer Management and Research, January 2018
Altmetric Badge

Mentioned by

reddit
1 Redditor

Citations

dimensions_citation
13 Dimensions

Readers on

mendeley
19 Mendeley
Title
Treatment and outcomes of non-small-cell lung cancer patients with high comorbidity
Published in
Cancer Management and Research, January 2018
DOI 10.2147/cmar.s151935
Pubmed ID
Authors

Jorge Rios, Rahul Gosain, Bernardo HL Goulart, Bin Huang, Margaret N Oechsli, Jaclyn K McDowell, Quan Chen, Thomas Tucker, Goetz H Kloecker

Abstract

The life expectancy of untreated non-small-cell lung cancer (NSCLC) is dismal, while treatment for NSCLC improves survival. The presence of comorbidities is thought to play a significant role in the decision to treat or not treat a given patient. We aim to evaluate the association of comorbidities with the survival of patients treated for NSCLC. We performed a retrospective study of patients aged ≥66 years with invasive NSCLC between the years 2007 and 2011 in the Surveillance, Epidemiology, and End Results Kentucky Cancer Registry. Comorbidity was measured using the Klabunde Comorbidity Index (KCI), and univariate and multivariate logistic regression models were used to measure association between receiving treatment and comorbidity. Kaplan-Meier plots were constructed to estimate time-to-event outcomes. A total of 4014 patients were identified; of this, 94.9% were white and 55.7% were male. The proportion of patients who did not receive any treatment was 8.7%, 3.9%, 19.1%, and 23.5% for stages I, II, III, and IV, respectively (p<0.0001). In multivariate analysis, older age, higher stage, and higher comorbidity (KCI ≥3) were associated with a lower likelihood of receiving any treatment. The median overall survival (OS) for untreated and KCI=0 was 17.7 months for stages I and II, 2.3 months for stage III, and 1.3 months for stage IV. The median OS for treated and KCI=0 was 58.9 months for stages I and II, 16.8 months for stage III, and 5.8 months for stage IV (p<0.01). Treatment was an independent predictor of OS in multivariate analysis that included KCI scores. Our data suggest that lung cancer patients may derive a survival benefit from therapies, regardless of the presence of comorbidities, although the degree of benefit seems to decrease with higher KCI scores.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 19 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 19 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 4 21%
Researcher 3 16%
Student > Ph. D. Student 2 11%
Unspecified 1 5%
Lecturer 1 5%
Other 2 11%
Unknown 6 32%
Readers by discipline Count As %
Medicine and Dentistry 5 26%
Engineering 2 11%
Unspecified 1 5%
Psychology 1 5%
Biochemistry, Genetics and Molecular Biology 1 5%
Other 2 11%
Unknown 7 37%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 January 2018.
All research outputs
#20,461,148
of 23,018,998 outputs
Outputs from Cancer Management and Research
#1,404
of 2,016 outputs
Outputs of similar age
#378,196
of 442,354 outputs
Outputs of similar age from Cancer Management and Research
#36
of 41 outputs
Altmetric has tracked 23,018,998 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,016 research outputs from this source. They receive a mean Attention Score of 3.0. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 442,354 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 41 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.